AstraZeneca to present the latest cardiovascular research

AstraZeneca and MedImmune will present new data from its Cardiovascular, Renal and Metabolism (CVRM) portfolio for the treatment of patients with overlapping diseases and multiple risk factors.

AstraZeneca and its global biologics research and development arm MedImmune will demonstrate the latest findings at the European Society of Cardiology (ESC) Congress in Munich, Germany, between 25 and 29 August.

The Anglo-Swedish pharma will reveal new real-world evidence on patients most at risk of future cardiovascular events, including death, underlining the need for improved secondary prevention including dual antiplatelet therapy (DAPT).

The latest research aims to inform clinical practice in patients with type 2 diabetes treated with glucose-lowering drugs who may also have coronary artery disease and/or experienced a prior heart attack or stroke.

Cardiologists will also be able to hear more about the evaluation of real-world consequences in sub-optimal renin-angiotensin-aldosterone system (RAAS) inhibitor dosing in the treatment of heart failure patients with hyperkalaemia, aiming to ensure patients receive optimum cardio-renal protection.

Additionally, AstraZeneca is going to present phase 2a results from the first collaboration between MedImmune and the TIMI Study Group, which indicate the potential therapeutic benefit of MEDI 6012, a lecithin-cholesterol acyltransferase (LCAT), for the treatment of atherosclerosis in patients having experienced the most serious type of heart attack.

[caption id="attachment_44278" align="alignleft" width="90"] Ludovic Helfgott[/caption]

Ludovic Helfgott, vice president, Cardiovascular, Renal and Metabolism at AstraZeneca, said: “At ESC, we continue to explore the intricacies of cardio-renal and metabolic risk with our determination to improve patient outcomes.”

“The data to be presented in Munich this year underscores the persistent ischaemic risk in patients with additional risk factors such as diabetes or multi-vessel disease and demonstrates clinical benefits in heart failure for patients with hyperkalaemia.”

Cardiovascular, renal and metabolic diseases together form one of AstraZeneca’s main therapy areas and platforms for future growth.

By following the science to understand more clearly the underlying links between the heart, kidney and pancreas, AstraZeneca is currently investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression.